GlassScriptPhysician profile
Bohdan Fedirko
NPI 1033163563
$10,338.89
in general payments reported to CMS, 2019-2025
34 companies · $2,003 in 2025
The $2,003 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $780 · 2021: $1,771 · 2022: $1,455 · 2023: $1,509 · 2024: $1,561 · 2025: $2,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,072.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,721.69 | 2020-2025 | Jardiance |
| Pfizer INC. | $1,132.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,026.66 | 2019-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $906.12 | 2019-2025 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $902.44 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $832.68 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $443.17 | 2019-2025 | Wegovy, Ozempic |
| Amgen INC. | $389.04 | 2019-2023 | Repatha |
| Lilly USA, LLC | $366.23 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $302.34 | 2021-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $289.64 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $272.28 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $264.68 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $232.20 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.63 | 2020-2025 | Xifaxan |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $172.44 | 2019-2021 | |
| Abbott Laboratories | $128.49 | 2021-2023 | Mitraclip |
| Azurity Pharmaceuticals, INC. | $91.93 | 2023-2024 | Edarbi, Edarbi |
| Edwards Lifesciences Corporation | $90.68 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Arbor Pharmaceuticals, INC. | $87.59 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $85.90 | 2020-2021 | |
| Allergan, INC. | $72.44 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $57.88 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $54.48 | 2025 | |
| Astellas Pharma US INC | $36.04 | 2019-2022 | |
| Resmed Corp | $32.33 | 2025 | |
| Medtronic, INC. | $29.78 | 2021-2022 | |
| Horizon Therapeutics Plc | $26.04 | 2019-2020 | |
| Scpharmaceuticals INC. | $21.37 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $20.58 | 2024 | Arcalyst |
| Ironwood Pharmaceuticals, INC | $19.40 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.94 | 2025 | Opsumit, Uptravi |
| Nalpropion Pharmaceuticals LLC | $12.74 | 2019 | |
| Smith+Nephew, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bohdan Fedirko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.